Leerink Partnrs Has Pessimistic View of REGN Q1 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for Regeneron Pharmaceuticals in a report released on Tuesday, April 1st. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $7.07 for the quarter, down from their prior estimate of $7.56. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals' Q2 2025 earnings at $8.22 EPS, Q3 2025 earnings at $9.62 EPS, Q4 2025 earnings at $9.56 EPS, FY2025 earnings at $34.47 EPS and FY2026 earnings at $35.16 EPS.

A number of other research firms have also recently commented on REGN. UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. TD Cowen lowered their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price target for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Bank of America reiterated an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $966.88.

Regeneron Pharmaceuticals Price Performance

REGN traded down $10.97 during trading on Thursday, hitting $561.81. 307,223 shares of the stock traded hands, compared to its average volume of 690,081. The business has a 50 day moving average price of $674.46 and a 200 day moving average price of $772.53. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals has a twelve month low of $557.83 and a twelve month high of $1,211.20. The company has a market cap of $61.42 billion, a price-to-earnings ratio of 14.71, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the firm earned $11.86 EPS. The business's quarterly revenue was up 10.3% compared to the same quarter last year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $28,000. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the period. Tompkins Financial Corp purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $32,000. Finally, Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $36,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.63%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.